Dolby Laboratories filings document the regulatory disclosures of a technology licensing and cinema-products company whose Class A common stock trades on the New York Stock Exchange under DLB. Recent Form 8-K reports furnish quarterly and annual financial results, dividend declarations for Class A and Class B common stock, and related exhibits.
The company’s proxy and governance filings cover director elections, advisory executive-compensation votes, auditor ratification and executive incentive compensation arrangements. The filings also describe Dolby’s dual-class voting structure, with Class A and Class B common stock voting together on most stockholder matters except where law requires otherwise.
Dolby Laboratories director and 10% owner David Dolby received an equity award of 3,908 restricted stock units (RSUs) of Class A common stock on February 3, 2026. The RSUs were granted at a price of $0 per unit under the company’s 2020 Stock Plan.
Each RSU represents a contingent right to receive one share of Class A common stock that will vest on the earlier of the first anniversary of the grant date or the date immediately preceding Dolby’s 2027 annual stockholders’ meeting, as long as he continues to serve on the board. After this award, he beneficially owns 92,718 Class A shares, including the 3,908 unvested RSU shares that are subject to forfeiture until they vest.
Dolby Laboratories director Emily Rollins received an equity grant as part of her board compensation. On February 3, 2026, she was awarded 3,908 restricted stock units of Class A common stock at a price of $0 per share under Dolby’s 2020 Stock Plan.
Each unit represents one share that will vest on the earlier of the first anniversary of the grant date or the date immediately preceding Dolby’s 2027 annual stockholder meeting, as long as she continues serving on the board. After this grant, she beneficially owns 13,541 Class A shares, including the unvested units, which remain subject to forfeiture until they vest.
Dolby Laboratories director Peter C. Gotcher received an equity award of 3,908 restricted stock units (RSUs) of Class A Common Stock on February 3, 2026. The RSUs were granted at a price of $0 under Dolby’s 2020 Stock Plan.
Each RSU represents a right to receive one share of Class A Common Stock upon vesting. Vesting occurs on the earlier of the first anniversary of the grant date or the date immediately preceding Dolby’s 2027 annual meeting of stockholders, if Gotcher continues serving on the board.
After this grant, Gotcher beneficially owns 44,641 shares of Class A Common Stock, including 3,908 shares underlying unvested RSUs that are subject to forfeiture until they vest.
Dolby Laboratories director Anjali Sud reported a grant of 3,908 restricted stock units (RSUs) of Class A common stock on February 3, 2026 at a price of $0. The award was made under Dolby’s 2020 Stock Plan.
Each RSU represents a contingent right to receive one Dolby Class A share that vests on the earlier of the first anniversary of the grant date or the date immediately preceding Dolby’s 2027 annual meeting of stockholders, if she continues serving on the board. After this grant, she beneficially owns 16,079 Class A shares, including 3,908 unvested RSU-based shares that remain subject to forfeiture until they vest.
Dolby Laboratories director Tony A. Prophet received an equity award in the form of restricted stock units. On 02/03/2026, he was granted 3,908 restricted stock units of Class A common stock at a price of $0 per unit under the company’s 2020 Stock Plan.
Each unit converts into one share of Class A common stock upon vesting. Vesting will occur on the earlier of the first anniversary of the grant date or the day immediately before Dolby’s 2027 annual stockholders’ meeting, if he continues serving on the board. After this grant, he beneficially owns 13,015 Class A shares, including the unvested units, which are subject to forfeiture until they vest.
Dolby Laboratories director Avadis Tevanian reported an equity award and updated share holdings. On February 3, 2026, he received 3,908 restricted stock units (RSUs) of Class A common stock at $0 under Dolby’s 2020 Stock Plan.
Each RSU represents one share of Class A common stock and will vest on the earlier of the first anniversary of the grant date or immediately before Dolby’s 2027 annual shareholders’ meeting, contingent on his continued board service. Following this grant, he beneficially owns 3,908 shares directly through these RSUs and 62,670 shares indirectly held by the Avadis Tevanian Jr. and Nancy Tevanian Trust.
Dolby Laboratories senior executive John D. Couling reported a sale of company stock. On February 2, 2026, he sold 6,667 shares of Dolby Class A common stock at $64.885 per share. After this transaction, he beneficially owned 123,041 shares in total.
This total includes 55,114 shares of Class A common stock underlying restricted stock units. These restricted stock units are subject to forfeiture until they vest, meaning Couling’s ability to keep those shares depends on future vesting conditions being met.
Dolby Laboratories insider John Couling has filed to sell additional common shares under Rule 144. The notice covers 6,667 common shares to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services on or about 02/02/2026, with an aggregate market value of 432,588.30. The filing notes 60,884,768 common shares outstanding and lists the NYSE as the trading venue.
The shares to be sold were originally acquired from the issuer as restricted stock and performance shares on various grant dates between 12/15/2020 and 12/15/2023. Over the past three months, Couling previously sold 7,273 common shares on 12/11/2025 for gross proceeds of 500,018.75 and 6,164 common shares on 11/20/2025 for gross proceeds of 407,563.68.
Dolby Laboratories reported net income attributable to the company of $53.3 million for the fiscal quarter ended December 26, 2025, on revenue of $346.7 million, down modestly from $357.0 million a year earlier. Licensing remained the core driver, contributing $319.8 million, or 92% of total revenue.
Net income declined from $67.8 million as operating income fell to $62.2 million, partly reflecting higher restructuring charges of $10.5 million. Dolby generated $54.8 million in operating cash flow and ended the quarter with $643.8 million in cash and cash equivalents plus $83.7 million in restricted cash, after repurchasing $70.0 million of stock and paying $34.3 million in dividends.
Dolby Laboratories, Inc. reported that it has released its financial results for the fiscal quarter ended December 26, 2025 through a press release furnished as an exhibit. The filing itself does not detail the numbers but points readers to the accompanying press release for full results.
The company also declared a cash dividend of $0.36 per share on its Class A and Class B common stock, payable on February 18, 2026 to stockholders of record as of the close of business on February 10, 2026. Dolby reiterates that it shares important information through its websites, SEC filings, press releases, and public calls.